Integrated Diagnostics (Indi; Seattle), a molecular diagnostic company that was founded in 2009 and is focused on the use of blood-based proteomic tests, said it has raised $30.25 million from the closing of its Series B and $17 million in non-dilutive debt financing provided by Life Sciences Alternative Funding. The financing round was led by Baird Capital and joined by Indi's existing investors, InterWest Partners and the Wellcome Trust.
Read More
